NCCN Debuts New Guidelines for Myeloproliferative Neoplasms

Guidelines for the management of myeloproliferative neoplasms

Polycythemia vera, essential thrombocythemia, and primary myelofibrosis are collectively known as 'Philadelphia-negative classical myeloproliferative neoplasms (MPNs).' The discovery of new genetic aberrations such as Janus kinase 2 (JAK2) have enhanced our understanding of the pathophysiology of MPNs. Currently, the JAK2 mutation is not only a standard criterion for diagnosis but is also a new...

New mutations and pathogenesis of myeloproliferative neoplasms.

Myeloproliferative neoplasms (MPNs) are clonal disorders characterized by excessive production of mature blood cells. In the majority of classic MPN--polycythemia vera, essential thrombocythemia, and primitive myelofibrosis--driver oncogenic mutations affecting Janus kinase 2 (JAK2) or MPL lead to constitutive activation of cytokine-regulated intracellular signaling pathways. LNK, c-CBL, or SOC...

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) Myelodysplastic Syndromes

NCCN All recommendations are category 2A unless otherwise specified. See believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. NCCN To find clinical trials online at NCCN Member Institutions, click here: nccn.org/clinical_trials/physician.html. The NCCN Guidelines are a statement of evidence and consensus of t...

Continue NCCN . org NCCN Clinical Practice Guidelines in Oncology ( NCCN Guidelines TM ) Rectal Cancer

NCCN Publishes New Clinical Practice Guidelines for Vulvar Cancer.

FORT WASHINGTON, PA — It is estimated that more than 5,000 cases of Vulvar Cancer were diagnosed in the United States in 2015, and approximately 1,000 women died from the disease i . In order to provide comprehensive, up-to-date clinical treatment guidelines for this rare cancer, the National Comprehensive Cancer Network ® (NCCN ® ), an alliance of 26 of the nation’s leading cancer centers, has...